Becker Susan E
Potomac Hospital, Woodbridge, VA, USA.
Clin J Oncol Nurs. 2007 Oct;11(5):731-5. doi: 10.1188/07.CJON.731-735.
Hairy cell leukemia (HCL), comprising 2% of all leukemias, is a chronic disorder characterized by mononuclear cells with prominent cytoplasmic projections. For years, patients with HCL underwent splenectomies and then interferon alpha for treatment, which provided high response rates but low percentages of complete remission. More recent treatments with 2-chlorodeoxyadenosine result in 85%-90% complete remission, minimal toxicity, and lower rates of relapse using a single course of therapy. A second course of therapy can be administered if HCL continues to be resistant or recurs. New research using anti-CD22 recombinant immunotoxin BL22 is proving successful. With these latest chemotherapy options, patients' prognoses are optimistic.
毛细胞白血病（HCL）占所有白血病的2%，是一种慢性疾病，其特征是单核细胞具有明显的细胞质突起。多年来，HCL患者接受脾切除术，然后使用α干扰素进行治疗，这种治疗方法缓解率高，但完全缓解率低。最近使用2-氯脱氧腺苷进行治疗，单疗程治疗的完全缓解率可达85%-90%，毒性极小，复发率较低。如果HCL持续耐药或复发，可以进行第二疗程的治疗。使用抗CD22重组免疫毒素BL22的新研究已证明取得成功。有了这些最新的化疗选择，患者的预后较为乐观。
